The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 

Slides:



Advertisements
Similar presentations
Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T
Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Grace Younes, M.D., Togas Tulandi, M.D., M.H.C.M. 
Meta-analysis of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection  Na Huang, M.S., Bing Situ, M.S., Xiao.
Antagonists in poor-responder patients
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.
Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis  George Griesinger, M.D.,
Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of blastocyst-stage versus cleavage-stage embryos generated through.
Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.
Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Sang-Hee Yoon, M. D. , Ji Young Lee, M. D. , Soo-Nyung Kim, M. D
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials  Ana Cobo, Ph.D., César Diaz, M.D. 
The likelihood of live birth and multiple birth after single versus double embryo transfer at the cleavage stage: a systematic review and meta-analysis 
Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D
Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.
Aviad Cohen, M.D., Benny Almog, M.D., Togas Tulandi, M.D., M.H.C.M. 
Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D. 
The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility  Alexander M. Quaas, M.D.,
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles  Tsung-Hsien.
Lena Dain, M. D. , David Bider, M. D. , Jacob Levron, M. D
Cervical mucus removal before embryo transfer in women undergoing in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis.
Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response  Frank.
Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials  Valeria M.S.
Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis  Cui Hong Zheng, M.D., Ph.D.,
Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T
Robert F. Casper, M.D.  Fertility and Sterility 
Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study  Ahmet Erdem, M.D., Mehmet Erdem,
Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study  Frederic Mitri,
Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration 
A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization  Laura Detti, M.D., Daniel B. Williams, M.D., Jared.
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone 
Use of testicular versus ejaculated sperm for intracytoplasmic sperm injection among men with cryptozoospermia: a meta-analysis  Nikita Abhyankar, M.B.ChB.,
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
A randomized clinical trial of endometrial perfusion with granulocyte colony-stimulating factor in in vitro fertilization cycles: impact on endometrial.
Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.
How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis  Dimitra Kyrou,
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis  Reshef Tal,
Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Effect of letrozole at 2. 5 mg or 5
Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.
Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis.
Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.
Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis 
Progesterone level at oocyte retrieval predicts in vitro fertilization success in a short- antagonist protocol: a prospective cohort study  Shweta Nayak,
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis  Byung Chul Jee, M.D., Chang Suk Suh, M.D.,
Low versus atmospheric oxygen tension for embryo culture in assisted reproduction: a systematic review and meta-analysis  Carolina O. Nastri, Ph.D., Beatrice.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss  Lia A. Bernardi, M.D., Ronald N. Cohen, M.D., Mary D. Stephenson, M.D.,
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles 
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review.
Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization  Rongrong Tan, M.M.Sc., Danhua Pu,
Presentation transcript:

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis  Jinsong Xiao, M.D., Shuang Chang, B.S., Shuangyun Chen, M.D.  Fertility and Sterility  Volume 100, Issue 6, Pages 1594-1601.e9 (December 2013) DOI: 10.1016/j.fertnstert.2013.08.024 Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 1 (A) Forest plot of the comparison of the GnRH antagonist group versus the long-protocol GnRH agonist group for clinical pregnancy rate. (B) Forest plot of the comparison of the GnRH antagonist group versus the short-protocol GnRH agonist group for clinical pregnancy rate. Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 2 (A) Forest plot of the comparison of the GnRH antagonist group versus long-protocol GnRH agonist group for the number of oocytes retrieved. (B) Forest plot of the comparison of the GnRH antagonist group versus short-protocol GnRH agonist group for the number of oocytes retrieved. Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 3 (A) Forest plot of the comparison of the GnRH antagonist group versus the long-protocol GnRH agonist group for cycle cancellation rate. (B) Forest plot of the comparison of the GnRH antagonist group versus the short-protocol GnRH agonist group for cycle cancellation rate. Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 1 Quality of reporting of meta-analyses (QUOROM) statement flow diagrams. Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 3 Funnel plot of analyzed studies regarding clinical pregnancy rate. Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 4 Forest plot of the comparison of the GnRH antagonist group versus the long-protocol GnRH agonist group for stimulation period (days). Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 5 Forest plot of the comparison of the GnRH antagonist group versus the short-protocol GnRH agonist group for stimulation period (days). Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 6 Forest plot of the comparison of the GnRH antagonist group versus the long-protocol GnRH agonist group for the gonadotropin dosage (ampule). Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 7 Forest plot of the comparison of the GnRH antagonist group versus the short-protocol GnRH agonist group for the gonadotropin dosage (ampule). Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 8 Forest plot of the comparison of the GnRH antagonist group versus GnRH agonist group for endometrial thickness on the day of hCG administration (mm). Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 2 Forest plot of the comparison of the GnRH antagonist group versus GnRH agonist group for the clinical pregnancy rate. Fertility and Sterility 2013 100, 1594-1601.e9DOI: (10.1016/j.fertnstert.2013.08.024) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.